Lixte Biotechnology Hldgs Inc Stock Price, News & Analysis

Lixte Biotechnology Holdings has announced promising results from a pre-clinical study indicating that its lead compound LB-100 enhances the efficacy of standard therapies in small cell lung cancer (SCLC). The findings underpin a recently initiated Phase 1b clinical trial at City of Hope, exploring the combination of LB-100 with carboplatin, etoposide, and atezolizumab.

LB-100 was found to increase drug uptake in tumor cells without raising toxicity, supporting its potential as a transformative treatment for aggressive cancers.

On July 22, 2021, Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced positive pre-clinical research findings regarding its lead compound, LB-100. The study revealed that LB-100, when combined with BioMarin's vosoritide, significantly enhanced bone growth in a mouse model of achondroplasia, surpassing the effects of vosoritide alone. CEO John S. Kovach highlighted LB-100's potential for treating small cell lung cancer and advanced soft tissue sarcomas, emphasizing its unique status as the only PP2A inhibitor in clinical trials. Lixte aims to demonstrate LB-100's clinical benefits across various serious diseases.

Lixte Biotechnology Holdings, Inc. announced recognition for Julio Pimentel, a doctoral student, for his research on LB-100 in triple negative breast cancer (TNBC). Pimentel was awarded the National Latino Leader Award and a scholarship to present his findings at a conference in October 2021. His research showed that LB-100 effectively inhibits TNBC cells and enhances the effectiveness of standard chemotherapy drugs like paclitaxel and cisplatin. Lixte's CEO highlighted the potential of LB-100 as a novel therapeutic approach for TNBC, which represents 15-20% of breast cancer cases in the U.S.

Lixte Biotechnology Holdings (Nasdaq: LIXT) is set to present at the MoneyShow July Virtual Expo from July 13-15, 2021. The event is accessible to the public and will feature a presentation by CEO John S. Kovach, M.D., outlining the Phase 1b/2 clinical trial for the lead compound LB-100, targeting extensive stage small cell lung cancer. This innovative trial is conducted in partnership with the City of Hope. Lixte is committed to developing effective cancer therapies and has achieved promising results with its PP2A inhibitor.

On June 2, 2021, Lixte Biotechnology Holdings announced the enrollment of the first patient in a Phase 1b clinical trial for LB-100, a PP2A inhibitor, in combination with chemotherapy for extensive stage small cell lung cancer (ED-SCLC). The trial, conducted at City of Hope, aims to assess the therapeutic benefit of LB-100 alongside carboplatin, etoposide, and atezolizumab. Preclinical data suggests that LB-100 enhances chemotherapy effectiveness in animal models. Approximately 30,000 new cases of small cell lung cancer are diagnosed annually in the U.S., highlighting the urgent need for effective treatments.

Lixte Biotechnology Holdings, Inc. has appointed Regina Brown, CPA, as an independent director and audit committee chair. Her extensive experience in public accounting, compliance, and taxation is seen as a valuable asset as the company expands. Brown has over 30 years of experience working with a diverse clientele, including large corporations and those with international operations. This appointment is expected to enhance Lixte's governance and oversight.

Lixte Biotechnology Holdings (Nasdaq: LIXT) announced participation in the Sidoti & Company LLC Virtual Microcap Conference on May 19-20, 2021. CEO John S. Kovach will present on May 20 at 12:15 p.m. ET, discussing the lead drug candidate LB-100, which enhances the efficacy of various anticancer treatments. Lixte's pipeline includes studies for four aggressive cancers, targeting a market exceeding $5 billion. The company aims to leverage its unique IP and lack of clinical competition for LB-100 to capture significant market share.

Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced participation in the virtual Benzinga Global Small Cap Conference on May 13-14, 2021. CEO John S. Kovach highlighted the potential of their lead drug candidate, LB-100, which targets aggressive cancers like myelodysplastic syndromes and glioblastoma. With a market exceeding $5 billion, Lixte aims to improve cancer treatment through its novel approach, having demonstrated positive preclinical results. The company's pipeline includes three clinical studies and one pharmacology study focused on LB-100.

Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced on April 13, 2021, the appointment of Gil N Schwartzberg to its Board of Directors following the resignation of Winson Ho. Dr. John S. Kovach, CEO, expressed confidence in Schwartzberg's contributions, noting his experience in guiding the company since its inception. Schwartzberg, former Chairman and CEO of the City of Hope National Medical Center, brings extensive expertise in cancer treatment and research. Lixte continues its focus on developing innovative cancer therapies, notably its lead compound, LB-100.